Navigation Links
ReGear Life Sciences Closes $2.5 Million in Series A Financing Following $1M Investment by Stonewood Capital Management, Inc.
Date:3/24/2009

PITTSBURGH, March 24 /PRNewswire/ -- ReGear Life Sciences, makers of the ReBound(TM) Therapeutic Warming System, a revolutionary form of radio-frequency (RF) diathermy, today announced that it has closed a $2.5M Series A financing round following a $1M investment by Stonewood Capital Management, Inc.

"Given the current condition of the financial markets and the economy we are fortunate to have been able to attract such a great group of angel investors and close out the round with an investor as respected as Stonewood," said James (Chip) Hanlon, ReGear's President and CEO. "Participation by such a group of sophisticated investors is a testament to the potential of our products, the strength of our target markets and the abilities of our team."

ReGear received its early financial backing from the Pittsburgh Life Sciences Greenhouse and Innovation Works, opened the A round in July of 2008, and began realizing revenue late in the fourth quarter of 2008.

The funds will be used to drive growth and further expansion into the global sports medicine, physical medicine, rehabilitation, and chiropractic markets, and develop products for the home care markets. ReBound is rapidly gaining acceptance and is currently under evaluation by many major professional sports, physical therapy and rehabilitation organizations. ReBound is also being distributed by Game Ready, an industry leader in cold and compression products through a strategic alliance.

"We are delighted to be an investor in ReGear," said Stonewood Managing Director John Tippins, who has joined ReGear's board of directors. "The market for pain management products is growing every day due to the aging of the baby boomers. ReGear's diathermy technology has shown great promise in relieving pain and improving quality of life and the company is perfectly positioned to provide future therapeutic products into its target markets."

ReBound is a compact, portable, and simple-to-use therapeutic warming system that utilizes patented ReGear Diathermy(TM) technology. ReBound can be used to treat virtually any condition for which thermotherapy is indicated, including muscle spasms, joint contractures and pain associated with a variety of conditions such as osteoarthritis, soft tissue injuries, back disorders and more. No other method of thermotherapy targets deep tissue or provides sustained therapeutic warming over a broad targeted region as effectively as ReBound.

About ReGear Life Sciences

Based in Pittsburgh, PA, ReGear Life Sciences, Inc. develops and markets revolutionary products for the sports medicine, physical medicine, and rehabilitation sectors that relieve pain, accelerate recovery, and improve the quality of life. The company's flagship product, the ReBound Therapeutic Warming System, has been cleared for unattended use and delivers innovative deep tissue therapeutic warming through a patented system of comfortable body-part specific garments powered by a portable radio frequency (RF) ReGeneratorTM. For additional information, visit http://www.regearlife.com.

About Stonewood Capital Management

Stonewood Capital Management, Inc. is a Pittsburgh-based private equity firm seeking opportunities with companies with sales of $5 to $60 million as well as revenue-generating early stage companies. For further information on Stonewood, please see www.stonewoodcapital.com.


'/>"/>
SOURCE Pittsburgh Life Sciences Greenhouse
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Coventina Healthcare Enterprises, Inc. is Now ReGear Life Sciences, Inc.
2. Game Ready(TM) and ReGear Life Sciences(TM) Bring Innovative New Heat Therapy to Market
3. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
4. Edwards Lifesciences to Present at the Bear Stearns 20th Annual Healthcare Conference
5. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
6. Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference
7. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
8. Novavax CEO to Present at the 2007 UBS Global Life Sciences Conference
9. Cardiac Science to Present at the UBS Global Life Sciences Conference
10. Akers Biosciences, Inc. ABI or the Company Receipt of Further United States Military Contracts
11. DRAXIS to Present at the 2007 UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... January 18, 2017 , ... The Portee Insurance Agency, a family managed firm ... central Maryland and the DC region, is inaugurating a charity event aimed at fighting ... year, making it the #1 killer in America. However, heart disease is largely preventable, ...
(Date:1/18/2017)... ... January 18, 2017 , ... Michael ... new website for its Center for Biosimilars, announced Michael J. Hennessy Associates, Inc. ... in the field of biosimilars through thought leader interaction in, live video and ...
(Date:1/17/2017)... ... , ... January is National Stalking Awareness Month (NSAM), now in its fourteenth year, ... commit the crime of stalking, a very real danger to many in our community. ... stalking and other crimes. , “Stalking: know it. Name it. Stop it.”—so reads the theme ...
(Date:1/17/2017)... ... January 17, 2017 , ... Today, ... Dr. Carol Francis re-releases powerfully uplifting interview with medical expert and prolific author, ... endure and pass through tough times, Dr. Bernie Siegel energizes listeners to live ...
(Date:1/17/2017)... ... January 17, 2017 , ... Metro ... approach to infusing high speed technology into the fabric of an entire community. ... advancement of healthcare and wellness in a yet-to-be-named, health focused campus. Leading this ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... 2017   Seno Medical Instruments, Inc. , the ... through the development of an opto-acoustic (OA/US) imaging device, ... as SVP of Engineering. Mr. Miller previously served as ... with headquarters in Bothell, Washington . ... career to the development of innovative medical imaging products ...
(Date:1/18/2017)... -- Tarix Orphan LLC today announced that the U.S. Food ... (RPD) designation for the company,s drug candidate TXA127 for ... rare genetic skin disorder. There are currently no approved ... care. "The RPD designation for TXA127 in ... the FDA in this indication," said Richard Franklin ...
(Date:1/18/2017)... 18, 2017 After the recent election ... use of cannabis both for medical and recreational purposes are ... open to the use of cannabis, but the focus is ... Arcview Market Research, the North American legal cannabis market posted ... previous year. The research projects sales will grow at a ...
Breaking Medicine Technology: